Human Papillomavirus Vaccine

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Inflammatory Bowel Disease

Conditions

Inflammatory Bowel Disease, Uterine Cervical Dysplasia

Trial Timeline

Feb 1, 2010 → Jun 1, 2011

NCT ID

NCT01034358

About Human Papillomavirus Vaccine

Human Papillomavirus Vaccine is a approved stage product being developed by Merck for Inflammatory Bowel Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01034358. Target conditions include Inflammatory Bowel Disease, Uterine Cervical Dysplasia.

What happened to similar drugs?

7 of 20 similar drugs in Inflammatory Bowel Disease were approved

Approved (7) Terminated (2) Active (13)

✅Infliximab + Infliximab + InfliximabCelltrionApproved

🔄CT-P13CelltrionPhase 3

🔄Infliximab subcutaneous + Immunosuppressive AgentsCelltrionPhase 3

✅fidaxomicinAstellas PharmaApproved

✅RisankizumabAbbVieApproved

✅BezlotoxumabMerckApproved

🔄Fingolimod + Placebo ComparatorNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01928225	Phase 2	Completed	Sep 2, 2014	Mar 1, 2018	Cervical High Grade Squamous Intraepithelial Lesion
NCT00767897	Pre-clinical	Completed	Nov 1, 2011	Dec 1, 2018	Chronic Kidney Disease
NCT01034358	Approved	Completed	Feb 1, 2010	Jun 1, 2011	Inflammatory Bowel Disease

Competing Products

20 competing products in Inflammatory Bowel Disease

See all competitors

Product	Company	Stage	Hype Score
Infliximab + Infliximab + Infliximab	Celltrion	Approved	50
CT-P13	Celltrion	Phase 3	36
Subcutaneous infliximab CT-P13 Remsima®SC	Celltrion	Pre-clinical	22
Infliximab subcutaneous + Immunosuppressive Agents	Celltrion	Phase 3	47
fidaxomicin	Astellas Pharma	Approved	43
Eribulin + Adriamycin + Cyclophosphamide	Eisai	Phase 2	39
E6007 + E6007 + E6007 + E6007 + E6007 + E6007	Eisai	Phase 1	29
Placebo + MORF-057	Eli Lilly	Phase 2	42
Baricitinib + Baricitinib	Eli Lilly	Phase 2	35
LY3114062 SC + Placebo + LY3114062 IV	Eli Lilly	Phase 1	29
MORF-057 + Placebo	Eli Lilly	Phase 2	39
MORF-057	Eli Lilly	Phase 2	35
LY3009104	Eli Lilly	Phase 1	29
HRF2105 patch + Loxoprofen patch + placebo	Jiangsu Hengrui Medicine	Phase 2	31
Risankizumab	AbbVie	Approved	43
GC012F Injection infusion	AstraZeneca	Phase 1	36
AZD6793 + Placebo	AstraZeneca	Phase 1	29
Pembrolizumab	Merck	Phase 2	31
Gardasil vaccine	Merck	Pre-clinical	26
Bezlotoxumab	Merck	Approved	35